India, Oct. 22 -- What prompted the development of EASE 2.0, and how does it build on the capabilities of the first-generation platform?

Depression, anxiety and many neurological conditions are disorders of brain circuits, yet most treatment still relies on medication alone, and most brain stimulation devices deliver current without measuring how the brain responds. Clinicians using EASE 1.0 saw what portable neuromodulation could do for their patients, and asked us to take it further: more conditions, more settings, and richer insight into each patient's progress. That became the brief for EASE 2.0.

EASE 1.0 showed that portable, clinician-supervised neuromodulation can be delivered safely and at scale in Indian clinics. Patients have ...